Teva Pharmaceutical Industries Ltd (NYSE:TEVA) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 65,701,193 shares, a decline of 6.7% from the January 12th total of 70,392,179 shares. Approximately 6.5% of the company’s shares are sold short. Based on an average daily volume of 16,651,324 shares, the short-interest ratio is presently 3.9 days.
Teva Pharmaceutical Industries (TEVA) opened at $18.52 on Wednesday. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $37.94. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $18,430.00, a P/E ratio of -1.14, a price-to-earnings-growth ratio of 1.37 and a beta of 0.59.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.14. The firm had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The business’s revenue for the quarter was down 15.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.38 EPS. sell-side analysts expect that Teva Pharmaceutical Industries will post 2.73 earnings per share for the current fiscal year.
TEVA has been the topic of a number of research analyst reports. Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Credit Suisse Group restated an “underperform” rating and set a $8.00 price target (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 price target on the stock in a report on Friday, December 15th. Royal Bank of Canada set a $11.00 price target on Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 14th. Ten equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $21.26.
ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/teva-pharmaceutical-industries-ltd-teva-short-interest-update.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.